These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 33115645)

  • 1. Response to "Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19".
    Mastellos DC; Lambris JD
    Clin Immunol; 2021 Jan; 222():108617. PubMed ID: 33115645
    [No Abstract]   [Full Text] [Related]  

  • 2. Commentary on "Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy" by D.C. Mastellos et al.
    de Miranda Santos IKF; de Barros Cardoso CR
    Clin Immunol; 2021 Jan; 222():108618. PubMed ID: 33127564
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter to the Editor in response to the article 'Candidate drugs against SARS-CoV-2 and COVID-19'.
    Campesi I; Montella A; Franconi F
    Pharmacol Res; 2021 Jan; 163():105285. PubMed ID: 33160068
    [No Abstract]   [Full Text] [Related]  

  • 4. Decreased complement C3 levels are associated with poor prognosis in patients with COVID-19: A retrospective cohort study.
    Fang S; Wang H; Lu L; Jia Y; Xia Z
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107070. PubMed ID: 33039965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse drug reactions in SARS-COV-2 hospitalised patients: a case series with a focus on drug-drug interactions-comment.
    Pardo-Cabello AJ; Manzano-Gamero V; Belda-Rustarazo S; Giner-Escobar P
    Intern Emerg Med; 2021 Apr; 16(3):797-798. PubMed ID: 33517559
    [No Abstract]   [Full Text] [Related]  

  • 6. Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro.
    Clementi N; Scagnolari C; D'Amore A; Palombi F; Criscuolo E; Frasca F; Pierangeli A; Mancini N; Antonelli G; Clementi M; Carpaneto A; Filippini A
    Pharmacol Res; 2021 Jan; 163():105255. PubMed ID: 33096221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.
    Mastaglio S; Ruggeri A; Risitano AM; Angelillo P; Yancopoulou D; Mastellos DC; Huber-Lang M; Piemontese S; Assanelli A; Garlanda C; Lambris JD; Ciceri F
    Clin Immunol; 2020 Jun; 215():108450. PubMed ID: 32360516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-steroidal anti-inflammatory treatment during covid-19: friend or foe? Response to: 'Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)' by Giollo
    Monti S; Montecucco C
    Ann Rheum Dis; 2021 Feb; 80(2):e13. PubMed ID: 32354774
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of antimotility drugs in COVID-19 associated diarrhea.
    Kow CS; Hasan SS
    J Infect; 2021 Feb; 82(2):e19. PubMed ID: 32956731
    [No Abstract]   [Full Text] [Related]  

  • 10. Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID).
    Giollo A; Adami G; Gatti D; Idolazzi L; Rossini M
    Ann Rheum Dis; 2021 Feb; 80(2):e12. PubMed ID: 32321720
    [No Abstract]   [Full Text] [Related]  

  • 11. Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection.
    Tang M; Cai J; Tan J
    Med Clin (Barc); 2021 Jun; 156(11):576. PubMed ID: 33593637
    [No Abstract]   [Full Text] [Related]  

  • 12. High-throughput screening and evaluation of repurposed drugs targeting the SARS-CoV-2 main protease.
    Li Y; Zhang J; Duan Z; Wang N; Sun X; Zhang Y; Fu L; Liu K; Yang Y; Pan S; Shi Y; Zeng H; Guo G; Lai R; Zou Q
    Signal Transduct Target Ther; 2021 Sep; 6(1):356. PubMed ID: 34588418
    [No Abstract]   [Full Text] [Related]  

  • 13. Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19.
    Di Maria E; Martini P; Gennarelli M
    Pharmacol Res; 2021 Feb; 164():105402. PubMed ID: 33359911
    [No Abstract]   [Full Text] [Related]  

  • 14. Anaesthesia drugs, SARS-CoV-2, and the sigma-1 receptor: a complex affair. Comment on Br J Anaesth 2021; 127: e32-4.
    Jain A; Lamperti M; Doyle DJ; Lobo FA
    Br J Anaesth; 2021 Dec; 127(6):e215-e218. PubMed ID: 34635287
    [No Abstract]   [Full Text] [Related]  

  • 15. Administration of end-of-life drugs by family caregivers during covid-19: opportunity for future home prescribing plans.
    Julião M
    BMJ; 2020 Jun; 369():m2408. PubMed ID: 32554622
    [No Abstract]   [Full Text] [Related]  

  • 16. Considerations of the effects of commonly investigated drugs for COVID-19 in the cholesterol synthesis pathway.
    Gomez Marti JL; Brufsky AM
    Expert Opin Pharmacother; 2021 Jun; 22(8):947-952. PubMed ID: 33703986
    [No Abstract]   [Full Text] [Related]  

  • 17. The Inherent Unfairness of COVID-19 Drug Access Pathways.
    Spector-Bagdady K; Gravelin M; Weatherwax KJ; Shuman AG
    Am J Bioeth; 2020; 20(9):18-20. PubMed ID: 33505223
    [No Abstract]   [Full Text] [Related]  

  • 18. Metformin use amid coronavirus disease 2019 pandemic.
    Kow CS; Hasan SS
    J Med Virol; 2020 Nov; 92(11):2401-2402. PubMed ID: 32470199
    [No Abstract]   [Full Text] [Related]  

  • 19. Are glomerular patients treated with immunosupressed drugs more protected against sever SARS-Covid -2?
    Agraz-Pamplona I; Montoro B; Bury R; Soler MJ; Carro CG; Solans R; Bolufer M; Cortes J; Espinel E; Seron D
    Semin Arthritis Rheum; 2020 Dec; 50(6):e4. PubMed ID: 32994058
    [No Abstract]   [Full Text] [Related]  

  • 20. Administration of end-of-life drugs by family caregivers during covid-19 pandemic.
    Bowers B; Pollock K; Barclay S
    BMJ; 2020 Apr; 369():m1615. PubMed ID: 32332027
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.